Worse post TAVI ejection fraction recovery in coronary artery disease patients without revascularization

Original title: Impact of coronary artery disease on left ventricular ejection fraction recovery following transcatheter aortic valve implantation. Reference: Freixa X et al. Catheter Cardiovasc Interv. 2014;Epub ahead of print.

This single center study analyzed data form 56 consecutive patients with severe aortic stenosis and LVEF of ≤ 50% undergoing TAVI (transcatheter aortic valve implantation) between March 2006 and May 2012, receiving the Balloon-expandable Sapien valve or Sapien XT valve (Edwards Lifesciences; Irvine, California) and the self-expandable CoreValve (Medtronic; Minneapolis, MN). Approach, type and size of prosthesis were chosen by a multidisciplinary team.

Coronary artery disease (CAD) was defined as the presence of at least 1 stenosis ≥ 70% by visual estimation or a history of revascularization. A total of 44 patients (78.5%) presented coronary artery disease, though half of these patients underwent complete revascularization before valve implantation.

In those with incomplete revascularization vs. those without CAD or with CAD and revascularization, mortality was higher both in hospital (22.2% vs 0% respectively; p= 0.01) and at one year follow up (25.9% vs 3.5% respectively; p=0.019).

The incomplete revascularization group also obtained a higher rate of the composite of death, infarction and rehospitalization, mainly based on rehospitalization due to cardiac failure (37% vs 3.7%; p=0.002). 

At 3 months, patients with complete revascularization or absence of CAD saw better LVEF recovery than those with incomplete revascularization (p=0.007) and this tendency persisted at 12 months (p=0.020). According to the multivariable analysis, the last independent predictors of LVEF recovery at three months were higher baseline LVEF (p=0.004) and complete revascularization (p<0.001).

Conclusion

The present study shows an independent association between complete revascularization and recovery of LVEF in those patients with severe aortic stenosis undergoing TAVI.

Editorial Comment

It is important to weigh the risks and benefits of this procedure in very elderly patient with complex lesions. It is clear that complete revascularization will always be the better choice; however, most of operators, when treating 80 to 90 year old patients with severe aortic stenosis and chronic total occlusion of the right coronary artery with good collaterals, will first try TAVI. 

When possible, PCI is always recommended but, if not possible, we should consider the adverse impact on prognosis. Perhaps, in the clinical context of this population of patients, “reasonable” revascularization might be as good as complete revascularization.

SOLACI

More articles by this author

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...

The Two Sides of the Coin: What Do CHAMPION-AF and CLOSURE-AF Teach Us About Left Atrial Appendage Closure?

Letter to the editor: Juan Manuel Pérez Asorey Percutaneous left atrial appendage closure (LAAO) is currently going through one of the most interesting stages of...

CLOSURE-AF: Percutaneous Left Atrial Appendage Closure versus Medical Therapy in Atrial Fibrillation

Percutaneous left atrial appendage closure has been proposed as an alternative to anticoagulation in patients with atrial fibrillation and high bleeding risk; however, comparative...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...

Therapeutic strategies in carotid free-floating thrombus: evidence and controversies

Carotid free-floating thrombus (cFFT) is a rare entity with a high embolic risk, associated with acute neurological events such as stroke or transient ischemic...